Olmutinib

• CAT Number: I001363
• CAS Number: 1353550-13-6
• Molecular Formula: C₂₆H₂₆N₆O₂S
• Molecular Weight: 486.59
• Purity: ≥95%
• Synonyms: N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide
• Target: Protein Tyrosine Kinase/RTK
• Solubility: DMSO: ≥ 44 mg/mL
• Storage: Store at -20°C
• IUPAC Name: N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide
• InChI: InChI=1S/C26H26N6O2S/c1-3-23(33)27-19-5-4-6-21(17-19)34-25-24-22(11-16-35-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)
• InChIKey: FDMQDKQUTRLUBU-UHFFFAOYSA-N
• SMILES: CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)SC=C4

Olmutinib(CFAT: I001363) is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed for targeted oncology research. It irreversibly binds to mutant EGFR, particularly T790M and activating EGFR mutations, which are associated with resistance to first-generation TKIs. This mechanism inhibits EGFR-mediated signal transduction, effectively suppressing tumor cell proliferation and survival. Olmutinib is a critical tool for studying non-small cell lung cancer (NSCLC) and understanding acquired resistance mechanisms. Its specificity and potency make it invaluable for researchers exploring advanced therapeutic strategies and combination treatments in the field of precision oncology.